Status:
RECRUITING
Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSD
Lead Sponsor:
Alexion Pharmaceuticals, Inc.
Conditions:
Neuromyelitis Optica Spectrum Disorder
Eligibility:
All Genders
Phase:
PHASE2
PHASE3
Brief Summary
The primary purpose of this study is to evaluate the safety and efficacy of ravulizumab in pediatric participants with Neuromyelitis Optica Spectrum Disorder (NMOSD).
Eligibility Criteria
Inclusion
- Participants must be anti-AQP4 Ab-positive and have a diagnosis of NMOSD as defined by the 2015 international consensus diagnostic criteria.
- Complement inhibitor treatment-naïve participants must have had at least 1 attack or relapse in the last 12 months prior to the Screening Period.
- Expanded Disability Status Scale (EDSS) score ≤ 7.
- Eculizumab-experienced participants must be clinically stable per Investigator for 30 days and have been treated with eculizumab in Study ECU-NMO-303 for at least 90 days prior to screening with no missed doses within 2 months prior to Day 1.
- Participants who enter the study receiving supportive IST(s) (eg, corticosteroid, azathioprine \[AZA\], mycophenolate mofetil \[MMF\], methotrexate \[MTX\], tacrolimus \[TAC\], cyclosporin \[CsA\], or cyclophosphamide \[CYC\]) for the prevention of relapse, either in combination or monotherapy, must be on a stable dosing regimen of adequate duration prior to Screening and remain on a stable dosing regimen during the Screening Period.
- To reduce the risk of meningococcal infection (Neisseria meningitidis), all participants must be vaccinated against meningococcal infection.
- Documented vaccination for Hib and S pneumoniae at least 14 days prior to Day 1 according to national/local guidelines for the applicable age group.
Exclusion
- Use of rituximab within 3 months prior to screening.
- Currently treated with a biologic medications (other than eculizumab) that may affect immune system functioning, or has stopped treatment with a biologic medication that may affect immune system functioning, and 5 half lives of the medication have not elapsed by the time of the Screening Visit.
- Use of intravenous immunoglobulin (IVIg) or plasma exchange (PE) within 3 weeks prior to Screening.
- Participation in another investigational drug or investigational device study (other than Study ECU-NMO-303) within 5 half lives of that investigational product (if known) or 30 days before initiation of the first dose of study drug, whichever is longer.
- Use of immunomodulatory therapies for multiple sclerosis within 3 months prior to Screening.
Key Trial Info
Start Date :
June 23 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 2 2029
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT05346354
Start Date
June 23 2022
End Date
April 2 2029
Last Update
November 12 2025
Active Locations (21)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Washington D.C., District of Columbia, United States, 20010
2
Research Site
Miami, Florida, United States, 33136
3
Research Site
Boston, Massachusetts, United States, 02114
4
Research Site
St Louis, Missouri, United States, 63110